Anti-KDEL-coated nanoparticles: A promising tumor targeting approach for ovarian cancer?

Biochimie

Volumn 94, Issue 11, 2012, Pages 2391-2397

  Delie, Florence ^a   Ribaux, Pascale ^b   Petignat, Patrick ^b   Cohen, Marie ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

GRP78; GRP94; Nanoparticle; Ovarian cancer; Targeting

Indexed keywords

GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 94; KDEL PROTEIN; LACTIC ACID; MONOCLONAL ANTIBODY; NANOPARTICLE; PACLITAXEL; PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLUORESCENCE; HUMAN; HUMAN CELL; MICROSCOPY; OVARY CANCER;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NEOPLASM INVASIVENESS; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN SORTING SIGNALS;

EID: 84867396412     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2012.06.010     Document Type: Article

References (41)

1. A.M. Lutz, J.K. Willmann, C.W. Drescher, P. Ray, F.V. Cochran, N. Urban, and S.S. Gambhir Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology 259 2011 329 345
2. I. Ramirez, H.S. Chon, and S.M. Apte The role of surgery in the management of epithelial ovarian cancer Cancer Control 18 2011 22 30
3. S. Pignata, L. Cannella, D. Leopardo, C. Pisano, G.S. Bruni, and G. Facchini Chemotherapy in epithelial ovarian cancer Cancer Lett. 303 2011 73 83
4. A. Du Bois, and J. Pfisterer Future options for first-line therapy of advanced ovarian cancer Int. J. Gynecol. Cancer 15 Suppl. 1 2005 42 50
5. Q.J. Quinones, G.G. de Ridder, and S.V. Pizzo GRP78: a chaperone with diverse roles beyond the endoplasmic reticulum Histol. Histopathol. 23 2008 1409 1416
6. M.J. Lewis, and H.R. Pelham Ligand-induced redistribution of a human KDEL receptor from the golgi complex to the endoplasmic reticulum Cell 68 1992 353 364
7. A.S. Lee The glucose-regulated proteins: stress induction and clinical applications Trends Biochem. Sci. 26 2001 504 510
8. Y. Fu, and A.S. Lee Glucose regulated proteins in cancer progression, drug resistance and immunotherapy Cancer Biol. Ther. 5 2006 741 744
9. J. Zhang, Y. Jiang, Z. Jia, Q. Li, W. Gong, L. Wang, D. Wei, J. Yao, S. Fang, and K. Xie Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer Clin. Exp. Metastasis 23 2006 401 410
10. L. Zhang, S. Wang, Wangtao, Y. Wang, J. Wang, L. Jiang, S. Li, X. Hu, and Q. Wang Upregulation of GRP78 and GRP94 and its function in chemotherapy resistance to VP-16 in human lung cancer cell line SK-MES-1 Cancer Invest. 27 2009 453 458
11. A.S. Lee GRP78 induction in cancer: therapeutic and prognostic implications Cancer Res. 67 2007 3496 3499
12. J. Li, and A.S. Lee Stress induction of GRP78/BiP and its role in cancer Curr. Mol. Med. 6 2006 45 54
13. H. Takahashi, J.P. Wang, H.C. Zheng, S. Masuda, and Y. Takano Overexpression of GRP78 and GRP94 is involved in colorectal carcinogenesis Histol. Histopathol. 26 2011 663 671
14. R.K. Reddy, J. Lu, and A.S. Lee The endoplasmic reticulum chaperone glycoprotein GRP94 with Ca(2+)-binding and antiapoptotic properties is a novel proteolytic target of calpain during etoposide-induced apoptosis J. Biol. Chem. 274 1999 28476 28483
15. B.K. Shin, H. Wang, A.M. Yim, F. Le Naour, F. Brichory, J.H. Jang, R. Zhao, E. Puravs, J. Tra, C.W. Michael, D.E. Misek, and S.M. Hanash Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function J. Biol. Chem. 278 2003 7607 7616
16. M. Katsogiannou, L. Peng, C.V. Catapano, and P. Rocchi Active-targeted nanotherapy strategies for prostate cancer Curr. Cancer Drug Targets 2011
17. U.K. Misra, and S.V. Pizzo Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells Cancer Biol. Ther. 9 2010 142 152
18. M. Cohen, and P. Petignat Purified autoantibodies against glucose-regulated protein 78 (GRP78) promote apoptosis and decrease invasiveness of ovarian cancer cells Cancer Lett. 309 2011 104 109
19. F. Delie, P. Petignat, and M. Cohen GRP78 protein expression in ovarian cancer patients and perspectives for a drug targeting approach J. Oncol. 2012 1 5 Article ID 468615
20. B. Nuijen, M. Bouma, J.H. Schellens, and J.H. Beijnen Progress in the development of alternative pharmaceutical formulations of taxanes Invest. New Drugs 19 2001 143 153
21. A.K. Singha, A. Garg, and D. Aggarwal Paclitaxel and its formulations Int. J. Pharm. 235 2002 179 192
22. ©) coupled nanoparticles Int. J. Pharm. 331 2007 190 196
23. A. Cirstoiu-Hapca, F. Bucheger, L. Bossy, M. Kosinski, R. Gurny, and F. Delie Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells Eur. J. Pharm. Sci. 38 2009 230 237
24. A. Cirstoiu-Hapca, F. Buchegger, N. Lange, L. Bossy, R. Gurny, and F. Delie Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice J. Contr. Release 144 2010 324 331
25. L. Nobs, F. Buchegger, R. Gurny, and E. Allemann Biodegradable nanoparticles for direct or two-step tumor immunotargeting Bioconjug. Chem. 17 2006 139 145
26. U.K. Misra, M. Gonzalez-Gronow, G. Gawdi, and S.V. Pizzo The role of MTJ-1 in cell surface translocation of GRP78, a receptor for alpha 2-macroglobulin-dependent signaling J. Immunol. 174 2005 2092 2097
27. K.R. Geisinger, T.E. Kute, M.J. Pettenati, C.E. Welander, Y. Dennard, L.A. Collins, and M.E. Berens Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors Cancer 63 1989 280 288
28. I. Brigger, C. Dubernet, and P. Couvreur Nanoparticles in cancer therapy and diagnosis Adv. Drug Del. Rev. 54 2002 631 651
29. J.D. Heidel, and M.E. Davis Clinical developments in nanotechnology for cancer therapy Pharm. Res. 28 2011 187 199
30. G. Trapani, N. Denora, A. Trapani, and V. Laquintana Recent advances in ligand targeted therapy J. Drug Target. 20 2012 1 22
31. P.J. Mintz, J. Kim, K.A. Do, X. Wang, R.G. Zinner, M. Cristofanilli, M.A. Arap, W.K. Hong, P. Troncoso, C.J. Logothetis, R. Pasqualini, and W. Arap Fingerprinting the circulating repertoire of antibodies from cancer patients Nat. Biotechnol. 21 2003 57 63
32. D.J. Davidson, C. Haskell, S. Majest, A. Kherzai, D.A. Egan, K.A. Walter, A. Schneider, E.F. Gubbins, L. Solomon, Z. Chen, R. Lesniewski, and J. Henkin Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78 Cancer Res. 65 2005 4663 4672
33. R.J. Passarella, D.E. Spratt, A.E. van der Ende, J.G. Phillips, H. Wu, V. Sathiyakumar, L. Zhou, D.E. Hallahan, E. Harth, and R. Diaz Targeted nanoparticles that deliver a sustained, specific release of paclitaxel to irradiated tumors Cancer Res. 70 2010 4550 4559
34. Y. Yoneda, S.C. Steiniger, K. Capkova, J.M. Mee, Y. Liu, G.F. Kaufmann, and K.D. Janda A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy Bioorg. Med. Chem. Lett. 18 2008 1632 1636
35. L.H. Zhang, and X. Zhang Roles of GRP78 in physiology and cancer J. Cell Biochem. 110 2010 1299 1305
36. M.A. Arap, J. Lahdenranta, P.J. Mintz, A. Hajitou, A.S. Sarkis, W. Arap, and R. Pasqualini Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands Cancer Cell 6 2004 275 284
37. Y. Kim, A.M. Lillo, S.C. Steiniger, Y. Liu, C. Ballatore, A. Anichini, R. Mortarini, G.F. Kaufmann, B. Zhou, B. Felding-Habermann, and K.D. Janda Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand Biochemistry 45 2006 9434 9444
38. Y. Liu, S.C. Steiniger, Y. Kim, G.F. Kaufmann, B. Felding-Habermann, and K.D. Janda Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery Mol. Pharm. 4 2007 435 447
39. U.K. Misra, Y. Mowery, S. Kaczowka, and S.V. Pizzo Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis Mol. Cancer Ther. 8 2009 1350 1362
40. C.S. Cho, A. Kobayashi, R. Takei, T. Ishihara, A. Maruyama, and T. Akaike Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers Biomaterials 22 2001 45 51
41. K. Ulbrich, T. Hekmatara, E. Herbert, and J. Kreuter Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB) Eur. J. Pharm. Biopharm. 71 2009 251 256